CP21R7

Item no.	HY-100207-1mg
Manufacturer	MedChem Express
CASRN	125314-13-8
Amount	1 mg
Quantity options	100 mg 10mM/1mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.63
Formula	C19H15N3O2
Citations	[1]Gong L, et al. Discovery of potent and bioavailable GSK-3beta inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1693-6.<br/>[2]Patsch C, et al. Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. Nat Cell Biol. 2015 Aug;17(8):994-1003.
Smiles	O=C1C(C2=CN(C)C3=CC=CC=C23)=C(C4=CC(N)=CC=C4)C(N1)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	CP21
Available
Product Description	CP21R7 is potent GSK-3β inhibitor, with an IC50 of 1.8 nM; CP21R7 also shows inhibitory activitiy against PKCα, with an IC50 of 1900 nM.
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	317.34
Clinical Information	No Development Reported
Manufacturers Research Area	Cancer
Solubility	DMSO : ≥ 32 mg/mL
Target	GSK-3
Manufacturers Target	GSK-3
Isoform	GSK-3β
Manufacturers Pathway	PI3K/Akt/mTOR; Stem Cell/Wnt
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-100207-1mg-safety-datasheet.pdf